Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 1
2019 1
2020 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination.
Ramos RN, Tosch C, Kotsias F, Claudepierre MC, Schmitt D, Remy-Ziller C, Hoffmann C, Ricordel M, Nourtier V, Farine I, Laruelle L, Hortelano J, Spring-Giusti C, Sedlik C, Le Tourneau C, Hoffmann C, Silvestre N, Erbs P, Bendjama K, Thioudellet C, Quemeneur E, Piaggio E, Rittner K. Ramos RN, et al. Among authors: nourtier v. Clin Transl Immunology. 2022 May 8;11(5):e1392. doi: 10.1002/cti2.1392. eCollection 2022. Clin Transl Immunology. 2022. PMID: 35573979 Free PMC article.
Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer.
Béguin J, Foloppe J, Maurey C, Laloy E, Hortelano J, Nourtier V, Pichon C, Cochin S, Cordier P, Huet H, Quemeneur E, Klonjkowski B, Erbs P. Béguin J, et al. Among authors: nourtier v. Mol Ther Oncolytics. 2020 Sep 2;19:57-66. doi: 10.1016/j.omto.2020.08.020. eCollection 2020 Dec 16. Mol Ther Oncolytics. 2020. PMID: 33072863 Free PMC article.
By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
Kleinpeter P, Remy-Ziller C, Winter E, Gantzer M, Nourtier V, Kempf J, Hortelano J, Schmitt D, Schultz H, Geist M, Brua C, Hoffmann C, Schlesinger Y, Villeval D, Thioudellet C, Erbs P, Foloppe J, Silvestre N, Fend L, Quemeneur E, Marchand JB. Kleinpeter P, et al. Among authors: nourtier v. J Virol. 2019 May 15;93(11):e00207-19. doi: 10.1128/JVI.00207-19. Print 2019 Jun 1. J Virol. 2019. PMID: 30918073 Free PMC article.
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C, Thioudellet C, Hortelano J, Gantzer M, Nourtier V, Claudepierre MC, Sansas B, Préville X, Bendjama K, Quemeneur E, Rittner K. Remy-Ziller C, et al. Among authors: nourtier v. Hum Vaccin Immunother. 2018 Jan 2;14(1):140-145. doi: 10.1080/21645515.2017.1373921. Epub 2017 Oct 18. Hum Vaccin Immunother. 2018. PMID: 28925793 Free PMC article.